Index

A
accelerated approval/assessment 41
adaptive pathways in EU 42
criteria for 9–38
exceptional circumstances authorization 42
expanded access (compassionate use) 10
Health Canada review process 105
Humanitarian Use Device (HUD) 10
in Australia 90
Orphan Products Grants Program 11
review system in Japan 79
single-patient expanded access (emergency use) 11
submitted MAA 41–60
advanced therapy medicinal products (ATMPs) development 43
Advisory Committee (FDA) 4
Advisory Committee on Medicines (ACM) 98
Advisory Group for National Specialized Services (AGNSS) 65
Algeria 117, 120, 122, 125, 128
All Wales Medicines Strategy Group (AWMSG) 65, 66
Animal Model Qualification Program (AMQP) 6
APAC/ASEAN
clinical trial/marketing authorization requirements 124
market access/reimbursement/pricing 127
orphan drug designation 121
patient engagement/advocacy 119
rare disease definitions 116
application fee waivers 1, 10, 90
Argentina 115, 118, 121, 123, 126
Armenia 117, 120, 122, 125, 128
Australia
comparison against registered therapeutic goods 96–102
eligibility for orphan designation 92
financial viability of medicine 95
history of orphan drug development 89–102
Life-Saving Drug Program funding criteria 100
National Strategic Action Plan for Rare Diseases 90
ODD, obtaining 91
orphan designation (OD) application content 91–102
Orphan Drug Regulation vs. New Dosage Form 93
prevalence and incidence of condition 95
prevalence and incidence of the condition 95
priority review pathway 90
provisional approval pathway 90–102
refusal on grounds of safety 97
sharing assessment reports with EMA 98
Zolgensma submission 98
Australia-Canada-Singapore-Switzerland (ACSS) Consortium 107
Australian Orphan Drugs Program 89
Australian Register of Therapeutic Goods (ARTG) 95
avelumab case study
  FDA approval overview 31
tools used in 30–38

B
benefits/initiatives for sponsors
  application fee waiver 1
  Australia 89–102
  CRA tax incentives 106
eculizumab 51
  EMA incentives 2–3
  granted by FDA 1–38
  in United Kingdom 61–68
  market exclusivity 51
  multiple orphan designations 51
  preferential tax treatment 69–88
  rare and undiagnosed diseases by AMED 79–88
  Regulatory Review of Drugs and Devices Initiative 108
biologics license application (BLA)
  DDTs use 5
  market exclusivity 1
  submission fee waivers 1
  Zolgensma (onasemnogene abeparvovec) case study 54
Biomarker Qualification Program 5
biomarkers
  natural history studies 26
  qualification for rare disease 5
  regulatory acceptance of 5
to subset a condition 94–102
Brazil 115, 118, 121, 123, 126
breakthrough therapy designation 8–38, 30, 33
Brexit 61

C
Canada
  clinical trial applications and NDS 103–114
  exclusive approval of orphan drug 109
  federal government department incentives 107–114
  fee mitigation options 106–114
  foreign review/third-party data use in 106–114
  HPFB evaluation and licensing of drug 109
  mutual recognition with EU 109
  Notice of Compliance with Conditions (NOC/c) 105–114
  orphan drug history 103–114
  patented drug extension 109
  priority review 105–114
  Special Access Program (SAP) 105–114
tax incentives for research/development 106–114
tools/resources for development 103–114
  work-sharing with other regulatory authorities 107
  Canada Revenue Agency (CRA) 106
  Canadian Coordinating Office for Health Technology Assessment (CADTH) 107
  Canadian Institutes of Health Research (CIHR) 107
  Canadian Organization of Rare Disease (CORD) 107
  Care for Rare Project 107
  Center for Biologics Evaluation and Research (CBER) 4
  Center for Drug Evaluation and Research (CDER) 6
  Certificates of Supplementary Protection (CSP) 109
  chemotherapy, manufacturing, and controls (CMC)
  for marketing application 24
  Chile 115, 118, 121, 123, 126
  China 116, 119, 121, 124, 127
  clinical outcome assessments (COAs) 4
  CDER programs for 6
  examples of 7
  natural history studies 26
  patient experience use in 5–38
  clinical superiority criteria 18
  clinical trials/studies
  APAC/ASEAN requirements 124
  CTN/CTA schemes for unapproved medicines 97
  effectiveness in disease/condition 18
efficacy endpoints 25–38
historical (external) controls 25
HPFB application for 109
Japan 71–88
LATAM (Latin America) 123
natural history studies 26–38
patient recruitment and retention 24–38
regulatory and choice of country 24–38
  requirements in other countries 125
safety 25–38
Zolgensma 54
clinician-reported outcome measures (ClinROs) 6, 26
collaboration
EMA and FDA 47
Health Canada and international authorities 107
Japanese ministries and agencies 73
Colombia 115, 118, 126
Colombia* 123
Commission of Human Medicines (CHM) 61
Committee for Advanced Therapies (CAT) certification procedure for ATMPs 43–60
patient representation on 45
Committee for Orphan Medicinal Products (COMP) 39, 45
Common Drug Review (CDR) 110
Community Advisory Board (CAB) 45
compassionate use programs
APAC/ASEAN countries 124
availability in approved clinical trial protocol 43–60
Community Advisory Board (CAB) Program 45
for emapalumab 30
investigational drug use 10
Japanese programs for 77
orphan medicines in Greece 56
conditional marketing authorization for EU 52
for fast track approval 41–60
in United Kingdom 61–68
requirements in Japan 79
Connect 4 Children (C4C) 45
cross-sectional vs longitudinal studies 28

D
drug development tools (DDTs) 4–38
Drug Identification Number (DIN) 109

E
Early Access to Medicines Scheme (EAMS) 62–68
eculizumab (Soliris) development incentives 51
efficacy endpoints 25
Egypt 117, 120, 122, 125, 128

EMA (European Medicines Agency)
centrally authorized product pilot project 44
CHMP opinions on novel methodology 43
collaboration with other agencies 47
development tools 41–60
innovative development methods 43
novel methodologies qualification 43
pediatric research facilitation 45
rare disease patient organizations 47
sharing assessment reports with TGA 98
emapalumab case study
approval process for 27–38
FDA approval overview 29
end-of-life orphan medicines 65
E-Rare 44, 107
EU Framework Program for Research and Innovation 44
EU-funded research on orphan products 44–60
European Commission (EC) grant funding 44
European Medicines Agency (EMA). See also European Union (EU)
European Network for Health Technology Assessment (EUnetHTA) 44
European Network of Pediatric Research at the European Medicines Agency (Enpr-EMA) 45
European Organization for Rare Diseases (EURORDIS) 45
European Reference Networks (ERNs) 44
European Union. See also EMA, European Medicines Agency
European Union (EU) conditional marketing authorization 52
market access in 56
medicine exclusivity approval in 55–60
mutual recognition agreement with Canada 109
orphan medicine development 39
regulatory standards compared to US 51
EURORDIS Community Advisory Board (CAB) Program 45–60
exceptional circumstances marketing authorizations 42–60, 62
exclusivity. See market exclusivity expanded access (FDA) 10–38 expedited programs (FDA) 7–38
fast-track designation 7–38, 41, 90
FDA (US Food and Drug Administration)
  drug development tools 4–38
  expedited programs 7
  fast track designation 7
  history 1–38
  meetings during development 4–38
  orphan drug development 1
  Pediatrics Advisory Committee 5
  priority review vouchers 6
financial viability 94
Finkel, Marion J. 1
France 56
full switch. See Rx-to-OTC switch process

Genome Canada 107
Germany 56
Greece 56

Health Canada
  joint reviews with authorities 107
  legal framework 108
  orphan drug criteria 108
  planned regulatory system improvements 108
  regulatory activity of 103
Health Products and Food Branch (HPFB)
  clinical trial application and NDS 109
  licensing of drug production sites 109
Health Technology Assessment (HTA)
  criteria for OMPs in UK 65
  European network for 44
  highly specialized technologies (HST) program 65
Horizon 2020 research funding 44
Humanitarian Use Device (HUD) 10–38
Human Research Ethics Committee (HREC) 97

India 116, 119, 124, 127
Innovative Licensing and Access Pathway (ILAP) 63
INTERACT meeting 4

investigational new drug (IND), tools for 5
in vitro, in vivo, and clinical data 17–38
iterative development 42

Japan. See also Ministry for Health, Labor, and Welfare (MHLW)
  academia-oriented research 84
  accelerated review system 78–88
  AMED funded programs and resources 77–88
  benefits to sponsors 69–88
  cancellation of designation 81
  clinical development case study 83
  company-oriented clinical development 84
  company-oriented clinical development case studies 84
  factors 86
  international deployment 73
  new indication for known drugs 84
  new molecular entity 85
  obtaining ODD in 80
  orphan drug development 69
  re-examination period extension 70
  regulatory history 69
  unapproved drug authorization 77
Japan Agency for Medical Research and Development (AMED) 77
Jayne Holtzer Research Grants Program 12

Kazakhstan 117, 120, 122, 125, 128

Latin America (LATAM)
  clinical trials/marketing authorization requirements 123
  market access/reimbursement/pricing 126
  orphan drug designation 121
  patient engagement/advocacy 118
  rare disease definition 115
laws and regulations
  Coronavirus Response and Relief Supplemental Consolidated Appropriations Act (US) 7
  Federal Food, Drug, and Cosmetic Act (US) 5
  Food and Drug Regulations (Canada) 108
  Food and Drugs Act (Canada) 108
  Gene Technology Act (Australia) 97
Nan-byo designation 76–88
Orphan Drug Act (ODA) 1
Orphan Drug Regulations 69
Orphan Regulation 39
Patented Medicines Regulations 109
Pediatric Regulation 39
Pediatric Research Equity Act (PREA) 1
Pharmaceutical Affairs Act 69
Pharmaceutical and Medical Device Act (PMD Act) 80
Prescription Drug User Fee Act (PDUFA) 1
Public Health Service Act 5
Regulation (EC) No 141/2000 39
Research to Accelerate Cures and Equity (RACE) for Children Act 3
Therapeutic Goods Act 97
Therapeutic Goods Regulations 89
timeline in US 2
21st Century Cures Act 5
Life-Saving Drug Program (LSDP) funding 100
rule of rescue 99

M
major contribution to patient care (MC to PC) 19–38
Malaysia 116, 119, 121, 124, 127
market access
APAC and ASEAN 127
criteria for OMPs in UK 65
health technology assessment submission 110–114
Latin America (LATAM) 126
NHI list (Japan) 85
notice of compliance (NOC) 109
orphan drugs (US) 34–38
other countries 128
Pharmaceutical Benefits Advisory Committee (PBAC) 99–102
market exclusivity 1
in Australia 98
in Canada 109
orphan product in UK 61, 65
re-examination period extension 85
scope of approval 33, 55
marketing authorization application 150-day assessment timeline process (UK) 63–68
APAC/ASEAN requirements 124
Health Canada legal framework 108
HPFB evaluation and licensing 109
Latin American requirements 123
orphan drug development (Japan) 81
orphan medicine development (EU) 51–60
requirements in other countries 125
rolling review for (UK) 63
TGA regulatory approach 97–102
mechanism of action (MOA) 16, 17
mechanism of coordinated access (MoCA) for EU 43
medical plausibility description 48, 93
Medicines and Healthcare products Regulatory Agency (MHRA). See also UK (United Kingdom)
150-day assessment timeline application 63
incentives for orphan product development 61
patient engagement in licensing of medicines 64
patient engagement pilot program 63
regulation after Brexit 67
Mexico 115, 118, 121, 123, 126
Ministry for Health, Labor, and Welfare (MHLW). See also Japan
orphan designation criteria 69
orphan medicine collaboration 47

N
Nan-byo 76
national competent authorities
market access decisions 56–60
pricing/reimbursement for coordinated access 44
National Institute for Health and Care Excellence (NICE) 65
National Institute of Biomedical Innovation (NIBIO) 69
National Organization for Rare Disorders (NORD) 1
National Strategic Action Plan for Rare Diseases (the Action Plan) 91, 100
natural history studies
  biomarkers 26–38
  clinical outcome assessments 26
  examples 27
  patient population 26–38
  types of 27
new drug application (NDA)
  DDTs use 5
  market exclusivity 1
  submission fee waivers 1
New Drugs Committee (NDC) 66
New Zealand 117, 120, 122, 125, 128
nitisinone approval 109
nonclinical studies 24–38
Notice of Compliance with Conditions (NOC/c) 105
novel methodologies for medicine development 43–60
NPO Advocacy Service for Rare and Intractable Diseases (ASrid) 79
International Rare Disease Research Consortium (IRDiRC) 107

O
observer-reported outcome measures (ObsROs) 6, 26
Office of Orphan Product Development (FDA) 1
off-label/unapproved use
  acceleration of use in Japan 74
  Australian clinical trial use 97
  high medical need drug evaluation (Japan) 76–88
orphan designation
  annual report submission 51–60
  other countries 122
  sponsor’s guide to 46
orphan designation application content 47–60
  description of the condition 48–60
  description of the stage of development 51–60
  drug substance name 47–60
  in Japan 82
  manufacturers 48
  other methods for diagnosis, prevention, or treatment of the condition 50–60
  proposed indication and anatomical therapeutic chemical classification system 47
  scientific content 48–60
  sponsor/contact person 48
  steps in preparation (Australia) 91–102
  trade name, strength, pharmaceutical form, and route of administration 47
orphan designation (OD) process
  confirmation of orphan designation 46
  in Japan 81
  orphan designation (initial OD) 46
  timing of submissions 47
orphan designation request
  administrative information 15–38
  contribution to patient care 19–38
  data sources 20–38
  disease/condition explanation 15–38
  drug description and MOA 17–38
  for combination products 20
  hypothesis for clinical superiority 18–38
  in Australia 91–102
  in vitro, in vivo, and clinical data 17–38
  methodology 21
  orphan subset 19–38
  permanent-resident agent for foreign sponsor 22–38
  population estimate 20–38
  regulatory status 19–38
  request timing 22
  same drug (active moiety/principal molecular structure) 18–38
  scientific rationale 17–38
  specific indication vs disease for 16
  symptom or complication of disease 16
  verification of status 21–38
Orphan Drug Designation (ODD)
  already approved drugs 22
  amendment to 22–38
  annual reports of holder 23–38
  APAC/ASEAN 121
  cancellation of designation (Japan) 81
  content and format of request 15–38
  deficiency letters 22
  granting designation 22
  Health Canada criteria for 108–114
  Latin America 121
  ownership change for 23–38
  process overview 16
  publication of designation 23–38
  requirements
    Japan 80–88
    Australia 89
  revocation of designation 23–38
orphan drug/medicine product development 13–39
approval process 15
assessment of orphan similarity 53–60
case studies 27–38
case study 54–60
clinical studies 24–38
history 39–60
incentives 1–38, 41
Japanese regulatory agencies in 80
market access (US) 34
marketing authorization application 51–60
marketing authorization application (NDA/BLA) 23–38
nonclinical studies 24–38
obtaining ODD 14–38
orphan designation (OD) process 46–60
orphan regulations timeline (EU) 40
process of 52
resources for sponsors 45
rest of world 115
tools available for 41–60
types of studies in 27
types of studies used 28
United Kingdom 61
United States 1
OrphaNet 45, 107
Orphan Products Grants Program 11
orphan subset 19

P

pan-Canadian Oncology Drug Review (pCODR) 110
Path to a Cure (PTAC) Industry Award program 13
Patient and Clinician Engagement (PACE) meeting 66
patient engagement/advocacy 11
APAC/ASEAN 119
Canadian Organization of Rare Disease (CORD) 107–114
EMA activities 44–60
in Japan 79–88
in stages of development 12
in United Kingdom 63–68
LATAM 118
National Strategic Action Plan for Rare Diseases (Australia) 91
other countries 120
PACE meetings 66
timeline with FDA in development 13
with CDER 14
Patient Group Consultative Forum 64–68
patient registries 43–60, 80
patient-reported outcome measures (PROs) 6, 26
Patients and Consumers Working Party (PCWP) 45
Pediatric Committee (PDCO) 45
Pediatric NANBYO Support Network 80
performance outcome measures (PerFO) 6, 26
Peru 115, 118, 121, 123, 126
Pharmaceutical Benefits Advisory Committee (PBAC) (Australia) 99
Pharmaceuticals and Medical Devices Agency (PMDA) (Japan) 69
pharmacogenomics/biomarker consultations 76–88
regulatory science and strategy consultations 76–88
tools/resources for development 70
Philippines 116, 119, 121, 124, 127
postauthorization efficacy studies (PAES) 43
postmarketing safety measures (Japan) 73
Preapproval Advisory Committee (Product Specific) 4
pre-IND/IND number 20
priority medicines (PRIME) scheme 41–60
Zolgensma 55
priority review designation 9–38
Canada 105–114
in Japan 69–88
TGA review timeline 90–102
vouchers for (US) 8, 6–38
promising innovative medicine (PIM) designation 62, 62–68
protection 109

Q

Qualified Infectious Disease Product (QIDP) designation 10–38
Index

R

rare diseases
APAC/ASEAN definitions 116
based on Australian population 94
criteria in UK 61
definition in other countries 117
designation criteria in Japan 69
diseases-related registries in Japan 79
EU research 44
HST program criteria 65
Latin America/South America definitions 115
medical plausibility description of 48
prevalence estimation 25
significant benefit of treatment proposed 50
Rare Voices Australia (RVA) 91
real-world evidence (RWE) case studies 54–60
regenerative medicine advanced therapy (RMAT) designation 9–38
reimbursement/pricing
APAC and ASEAN 127
CADTH recommendation for 110
in Japan 73–88, 85
Latin America (LATAM) 126
other countries 128
sponsor subsidies (NIBIO) 69
treatment and management programs in Australia 90
rest of the world (RoW)
clinical trial and marketing authorization requirements 123
market access/reimbursement/pricing 126
orphan drug designation 121
patient engagement/advocacy 118
rare disease definition 115
retrospective vs prospective studies 27
risk management
patient registries used in 43–60
safety monitoring activity (Japan) 73
rule of rescue factors 100
Russia 117, 120, 122, 125, 128

timeframe of 75
scientific advice and protocol assistance
MHFW and PMDA consultations 69–88
MHRA service 62
OMP development 41–60
Scientific Research and Experimental Development program (SR&ED) Tax Incentive Program (Canada) 106
Scottish Medicine Consortium (SMC) 65
self-care environment. See also self-management
Singapore 116, 119, 121, 124
Slovakia 117, 120, 122, 128
small-, and medium-sized enterprises (SMEs) 41–60
South Korea 116, 119, 121, 124, 127
Special Access Program
Canada 105
SAP 108
sponsors
annual report submission 51
benefits in Australia 89–102
benefits in Japan 69
cancer treatment pilot project 44
exceptional circumstances authorization 42
incentives for OMPs development 41
INTERACT meetings 4
MoCA application for 44
name/address changes for 51
novel methodology development 43
OD application content 47–60
OMP development 46
patient access schemes (UK) 66
patient engagement utility for 45
request for CMA 42
request to enter PRIME 41
resources for product development 45
scientific information on application 48–49
Zolgensma case study 54
Sprinraza (nusinersen)
case study 85, 86
PMDA approval 86
Switzerland 117, 120, 122, 125, 128

tax credits/incentives 1, 3, 49, 56, 69, 95, 106
Thailand 116, 119, 121, 124, 127
Therapeutics Development Award (TDA) 13

S

SAKIGAKE designation system
as a package 72
eligibility criteria 74–88
example 76
prioritized policy 71–88
procedure for 74–88

Taiwan 116, 119, 121, 124, 127
Thailand 116, 119, 121, 124, 127
Therapeutics Development Award (TDA) 13
tools/resources
  drug development in canada  103
  Drug Development Tools (FDA)  5
  from MHRA  61
  from PMDA  70
  from TGA  90
  Turkey  117, 120, 122, 125, 128

U
UK (United Kingdom)
  Early Access to Medicines Scheme  62
  history  61
  Innovative Licensing and Access Pathway  63
  OMP reimbursement  65
  orphan designation and MAA submission  64–68
  orphan medicine definition (Wales)  66
  orphan medicine development  61
  promising innovative medicine (PIM) designation  62
  tools for orphan medicine development  61–68
  ultra-orphan medicine (Scotland)  66
  ultra-orphan medicines (Scotland)  66, 66–68
  United Kingdom (UK). See Medicines and Healthcare products Regulatory Agency (MHRA)
  United States. See FDA (Food and Drug Administration)

V
Vietnam  116, 119, 121, 124, 127

Z
Zolgensma (onasemnogene abeparvovec) case study
  conditional approval by EMA  54
  FDA/EMA approval overview  53
  Health Canada submission  109
  overview of approval in other countries  99
  TGA review  98–102